Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DVS-SR 50 mg | Drug | |||
| DVS-SR 100 mg | Drug | |||
| Placebo | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo. |
| Measure | Description | Time Frame |
|---|---|---|
| Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Wyeth is now a wholly owned subsidiary of Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beverly Hills | California | 90210 | United States | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34183490 | Derived | Zilcha-Mano S, Wang X, Wajsbrot DB, Boucher M, Fine SA, Rutherford BR. Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression. J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):579-584. doi: 10.1097/JCP.0000000000001435. | |
| 29140227 | Derived | Soares CN, Zhang M, Boucher M. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. CNS Spectr. 2019 Jun;24(3):322-332. doi: 10.1017/S1092852917000633. Epub 2017 Nov 15. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Northridge |
| California |
| 91324 |
| United States |
| Farmington | Connecticut | 06030 | United States |
| Washington D.C. | District of Columbia | 20037 | United States |
| Miami | Florida | 33173 | United States |
| St. Petersburg | Florida | 33702 | United States |
| Marietta | Georgia | 30060 | United States |
| Smyrna | Georgia | 30080 | United States |
| Libertyville | Illinois | 60048 | United States |
| New Orleans | Louisiana | 70115 | United States |
| Farmington Hills | Michigan | 48336 | United States |
| Clementon | New Jersey | 08021 | United States |
| Moorestown | New Jersey | 08057 | United States |
| New York | New York | 10021 | United States |
| New York | New York | 10024 | United States |
| Dayton | Ohio | 45408 | United States |
| Toledo | Ohio | 43623 | United States |
| Oklahoma City | Oklahoma | 73103 | United States |
| Portland | Oregon | 97210 | United States |
| Philadelphia | Pennsylvania | United States |
| Charleston | South Carolina | 29407 | United States |
| Columbia | South Carolina | 29201 | United States |
| Salt Lake City | Utah | 84107 | United States |
| Seattle | Washington | United States |
| Brown Deer | Wisconsin | 53223 | United States |
| 26709542 | Derived | McIntyre RS, Fayyad R, Mackell JA, Boucher M. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. Curr Med Res Opin. 2016;32(3):587-99. doi: 10.1185/03007995.2015.1136603. Epub 2016 Jan 13. |
| 26644956 | Derived | McIntyre RS, Fayyad RS, Guico-Pabia CJ, Boucher M. A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d. Prim Care Companion CNS Disord. 2015 Jun 4;17(3):10.4088/PCC.14m01741. doi: 10.4088/PCC.14m01741. eCollection 2015. |
| 25758058 | Derived | Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr;31(4):809-20. doi: 10.1185/03007995.2015.1020365. Epub 2015 Mar 26. |
| 24571916 | Derived | Soares CN, Endicott J, Boucher M, Fayyad RS, Guico-Pabia CJ. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectr. 2014 Dec;19(6):519-27. doi: 10.1017/S1092852914000066. Epub 2014 Feb 26. |
| 18507895 | Derived | Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008 Jul;24(7):1877-90. doi: 10.1185/03007990802161923. Epub 2008 May 27. |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided